GRCE Historical PE Ratio Notes

— Grace Therapeutics (ticker symbol: GRCE) is a specialty pharmaceutical company focused on developing innovative, proprietary drug formulations to address unmet medical needs in rare diseases, particularly within the central nervous system & oncology sectors. The company leverages advanced drug delivery technologies to improve the safety, efficacy, & patient experience of existing therapeutics, often reformulating approved drugs for new indications or enhanced delivery. This business model means that GRCE's revenue streams are heavily reliant on the success of its clinical development pipeline & regulatory approvals, which can lead to fluctuating earnings over time. When reviewing GRCE's historical PE ratio (price to earnings ratio), it's important to note that as a smaller biotech firm, earnings may be irregular or even negative during heavy R&D phases, resulting in high or undefined PE ratios. Periods of successful product launches or strategic partnerships might compress the PE ratio due to rising earnings, while setbacks such as clinical failures cause volatility. Thus, the historical PE trends for GRCE not only reflect investor sentiment regarding its growth prospects, but also the inherent risks & milestones typical of the biotech sector. Understanding these industry dynamics is crucial as you analyze the company's historical valuation metrics.

On this page we presented the GRCE Historical PE Ratio information for Grace Therapeutics' stock. The average GRCE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 7.3. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average GRCE historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this GRCE historical PE result, against the recent PE: when this page was posted on 4/24/2026, the most recent closing price for GRCE had been 2.30, and the most recent quarterly earnings result, annualized, was 0.4. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent GRCE PE on 4/24/2026 based on annualized quarterly EPS was 5.7. Based on GRCE's history, that recent PE is low relative to the historical average, with the recent PE 21.9% lower than the historical average PE across our data set for Grace Therapeutics.

For self directed investors doing their due diligence on GRCE or any other given stock, valuation analysis for GRCE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Grace Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for GRCE. Thanks for visiting, and the next time you need to research GRCE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.